AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Canopy Growth Corporation
Video analysis: CGC
All videosNo video analysis for this stock yet. Request one from our team.
News: CGC
Canopy Growth's Business Is Improving. So Why Isn't the Stock Performing Better?
Canopy Growth recently reported incrementally stronger results, but the stock continues to languish. Slow legalization progress and share dilution keeps weighing on its performance.
Canopy Growth Reminds Shareholders to Vote Ahead of September 23 Deadline
SMITHS FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth”, “our”, “we” or the “Company”) (TSX: WEED) (Nasdaq: CGC), a leading global company committed to bettering lives through cannabis, today reminds shareholders to vote ahead of its Annual General and Special Meeting of shareholders (the “Meeting”) scheduled for Friday, September 25, 2026, at 1:00 p.m. ET. To ensure their votes are counted at the Meeting, shareholders should submit their vote no later than 1:00 p.m.
Canopy Growth (NASDAQ:CGC) vs. Clene (NASDAQ:CLNN) Financial Comparison
Canopy Growth (NASDAQ: CGC - Get Free Report) and Clene (NASDAQ: CLNN - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk. Valuation and Earnings This table compares Canopy Growth
Canopy Growth Corporation (NASDAQ:CGC) Receives Average Recommendation of “Hold” from Brokerages
Shares of Canopy Growth Corporation (NASDAQ: CGC - Get Free Report) have been assigned a consensus rating of "Hold" from the five ratings firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating
Canopy Growth Broadens Australian Medical Cannabis Portfolio With New Formats and Formulations
SMITHS FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth”, “our”, “we” or the “Company”) (TSX: WEED) (Nasdaq: CGC), a leading global company committed to bettering lives through cannabis, today announced a broadening of its medical cannabis portfolio in Australia across its Spectrum Therapeutics, Spectrum Therapeutics Reserve, 7ACRES, Tweed and Twd. brands. The expansion introduces two new product formats, and new formulations within its existing oil and softgel ranges.
Canopy Growth's Revenue Grew 13% Last Quarter. Investors Barely Reacted.
Canopy Growth's revenue increased 13% year over year in its most recent fiscal quarter. Adjusted gross margin improved, while EBITDA losses narrowed sharply.
Should You Buy Canopy Growth Stock on the Rebound?
Canopy Growth is a large Canadian marijuana company. Over the past year, it has strengthened its financial position and made an acquisition.
Better Cannabis Stock to Buy Right Now: Canopy Growth or Tilray Brands?
Tilray is seeing more revenue from beverages than from cannabis. Canopy's debt situation drags down its growth potential.
